The Competition Commission of India has approved three major combinations.
In a tweet, CCI said it had approved RPG Life Sciences acquiring seven brands of Sun Pharmaceutical Industries. Earlier this year, Sun Pharmaceutical had signed a deal in this regard with RPG, for Rs 41 crore. The move is in line with the company’s strategy to focus on formulations. The acquired brands are primarily in the respiratory and urology segments.
In another tweet, CCI said it had approved the proposed restructuring of Fortis Group, which includes de-merger of the pathology business, SRL Labs. The latter would be merged with Fortis Malar Hospitals and the entity renamed SRL Ltd, to be listed on the National Stock Exchange.
Fortis’ board approved the de-merger in August. Once through, all the group’s diagnostics business would come under the entity which is currently Fortis Malar. The latter’s hospitals business will be sold to Fortis Healthcare. For the composite scheme, Fortis Malar would issue and allot 0.98 fully paid-up equity shares of Rs 10 each for every one equity share of Rs 10 each held by them in Fortis Healthcare.
Full Content: Business Standard
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DirecTV and Disney Resolve Dispute, Restore Programming for Subscribers
Sep 15, 2024 by
CPI
UK Antitrust Authority Raises Concerns Over Vodafone-Three Merger
Sep 15, 2024 by
CPI
Brazilian Supreme Court Lifts Freeze on Starlink Accounts, Transfers $3.3 Million to National Treasury
Sep 15, 2024 by
CPI
Steptoe Expands Antitrust Practice with Key London Hire
Sep 15, 2024 by
CPI
Instant Ad Auctions at the Heart of Google’s Federal Monopoly Case
Sep 15, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández